3 Beaten-Down Stocks With Rebound Potential This Earnings Season

The article highlights three underperforming stocks—Scholar Rock (SRRK), Globant (GLOB), and NiCE (NICE)—as potential high-risk, high-reward plays ahead of their upcoming earnings reports. Biotech firm Scholar Rock, down 33% YTD despite strong Phase 3 data for its lead SMA drug, faces a Q3 report on Nov 14 where investors will seek updates on its pipeline and cash position. IT services provider Globant, down 70% YTD, needs to demonstrate its ability to convert its $3.7 billion AI pipeline into revenue and profit. Meanwhile, customer engagement software maker NiCE, down nearly 25% YTD despite cloud/AI growth and a recent generative AI acquisition, could see a rebound with improved fundamentals, as analysts remain largely bullish on all three for significant upside.

Analysis

The article identifies three significantly underperforming stocks—Scholar Rock (SRRK), Globant (GLOB), and NiCE (NICE)—as potential high-risk, high-reward opportunities for risk-tolerant investors ahead of their upcoming earnings reports. Despite substantial year-to-date declines, the general sentiment is moderately positive and speculative, reflecting the potential for asymmetric upside if key catalysts materialize. Each company faces a pivotal earnings call to either confirm or challenge current market skepticism.

Scholar Rock (SRRK), down 33% YTD due to manufacturing concerns, possesses a lead SMA drug, apitegromab, with robust Phase 3 data and 2026 approval potential, alongside a 54% lean mass preservation in a Phase 2 study. Investors will monitor its Q3 report (Nov 14) for pipeline updates and cash runway, given projected 76-cent losses per share. Globant (GLOB), down 70% YTD, must demonstrate conversion of its $3.7 billion AI pipeline into revenue and profit, as its Q2 was middling and prior guidance suggested flat sales.

NiCE Ltd. (NICE), despite a 25% YTD decline, shows strengthening annual recurring revenue driven by cloud and AI, bolstered by its Cognigy acquisition, projecting 7% YOY full-year revenue growth. Falling short interest by 12% suggests mounting optimism, with analysts largely bullish across all three companies. For instance, 13 of 14 analysts rate SRRK a Buy with 65%+ upside, while 8 of 14 rate NICE a Buy with 57% upside potential.

Key Decisions for Investors

• For Scholar Rock (SRRK), investors should closely monitor Q3 earnings for updates on apitegromab's clinical progress, pipeline developments, and the company's cash runway towards potential 2026 FDA approval.
• Globant (GLOB) investors should scrutinize the upcoming earnings report for tangible evidence of AI pipeline conversion into revenue, profit, and margin expansion, given prior guidance for flat sales.
• NiCE Ltd. (NICE) investors should observe earnings for broad fundamental improvements and confirmation of its cloud and AI strategy's impact on recurring revenue, especially following the Cognigy acquisition.
• Given the speculative nature and significant YTD declines, investors should weigh the potential for asymmetric upside against the inherent risks, recognizing that analyst optimism, while high, is not universally shared across all three companies.